Particle.news
Download on the App Store
4 ARTICLES
·
6d ago

P2Y12 Inhibitors Outperform Aspirin in Preventing Heart Attacks and Strokes Without Raising Bleeding Risk

A meta-analysis of five trials in more than 16,000 patients showed a 23% drop in major cardiovascular events over four years with P2Y12 monotherapy replacing aspirin

Image
THIS Common Prescription Drug Prevents Heart Attack and Stroke Without Any Side Effects, Say Scientists

Overview

  • The study pooled individual patient data from five randomized trials involving 16,117 coronary artery disease patients who transitioned from dual therapy after PCI to either P2Y12 inhibitor or aspirin monotherapy.
  • P2Y12 inhibitor therapy was linked to a 23% lower risk of combined cardiovascular death, heart attack or stroke over an average follow-up of four years compared with aspirin.
  • Major bleeding rates did not differ significantly between P2Y12 inhibitor and aspirin groups, indicating that switching to P2Y12 monotherapy does not increase bleeding risk.
  • The analysis found that treating 46 patients with a P2Y12 inhibitor instead of aspirin after dual therapy would prevent one cardiovascular death, heart attack or stroke.
  • Researchers note that the medium-term benefits may not extend indefinitely and recommend large-scale, long-term trials to assess outcomes beyond four years.